Tumor necrosis factor-alpha converting enzyme: Implications for ocular inflammatory diseases

International Journal of Biochemistry and Cell Biology

Volumn 42, Issue 7, 2010, Pages 1076-1079

  Ramana, Kota V ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Eye; Inflammation; TACE; TNF alpha; Uveitis

Indexed keywords

CYTOKINE; GROWTH FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR; ADAM PROTEIN; TUMOR NECROSIS FACTOR-ALPHA CONVERTASE;

BLINDNESS; CELLULAR IMMUNITY; CLINICAL TRIAL; CROHN DISEASE; DISEASE MARKER; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LOCALIZATION; ENZYME MODIFICATION; ENZYME SPECIFICITY; ENZYME STRUCTURE; EYE DISEASE; EYE INFLAMMATION; GLAUCOMA; HUMAN; INFLAMMATORY DISEASE; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; RETINA MACULA AGE RELATED DEGENERATION; RHEUMATOID ARTHRITIS; SHORT SURVEY; UVEITIS; ANIMAL; CHEMISTRY; ENZYMOLOGY; EYE; INFLAMMATION; METABOLISM; PATHOLOGY;

ADAM PROTEINS; ANIMALS; ENZYME ACTIVATION; EYE; HUMANS; INFLAMMATION;

EID: 77953537922     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biocel.2010.03.011     Document Type: Short Survey

References (28)

1. Ardoin S.P., Kredich D., Rabinovich E., Schanberg L.E., Jaffe G.J. Infliximab to treat chronic noninfectious uveitis in children: retrospective case series with long-term follow-up. Am J Ophthalmol 2007, 144:844-849.
2. Arribas J., Esselens C. ADAM17 as a therapeutic target in multiple diseases. Curr Pharm Des 2009, 15:2319-2335.
3. Black R.A., Rauch C.T., Kozlosky C.J., Peschon J.J., Slack J.L., Wolfson M.F., et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997, 385:729-733.
4. Cantarini L., Tinazzi I., Caramaschi P., Bellisai F., Brogna A., Galeazzi M. Safety and efficacy of etanercept in children with juvenile-onset Behcets disease. Int J Immunopathol Pharmacol 2009, 22:551-555.
5. Cook E.B., Stahl J.L., Graziano F.M., Barney N.P. Regulation of the receptor for TNF-alpha, TNFR1, in human conjunctival epithelial cells. Invest Ophthalmol Vis Sci 2008, 49:3992-3998.
6. DasGupta S., Murumkar P.R., Giridhar R., Yadav M.R. Current perspective of TACE inhibitors: a review. Bioorg Med Chem 2009, 17:444-459.
7. Evans S.V. SETOR: hardware lighted three-dimensional solid model representations of macromolecules. J Mol Graphics 1993, 11:134-138.
8. Federici M., Hribal M.L., Menghini R., Kanno H., Marchetti V., Porzio O., et al. Timp3 deficiency in insulin receptor-haploinsufficient mice promotes diabetes and vascular inflammation via increased TNF-alpha. J Clin Invest 2005, 115:3494-3505.
9. Franchimont N., Lambert C., Huynen P., Ribbens C., Relic B., Chariot A., et al. Interleukin-6 receptor shedding is enhanced by interleukin-1beta and tumor necrosis factor alpha and is partially mediated by tumor necrosis factor alpha-converting enzyme in osteoblast-like cells. Arthritis Rheum 2005, 52:84-93.
10. Gill S.E., Huizar I., Bench E.M., Sussman S.W., Wang Y., Khokha R., et al. Tissue inhibitor of metalloproteinases 3 regulates resolution of inflammation following acute lung injury. Am J Pathol 2010, 176:64-73.
11. Hahn D., Pischitzis A., Roesmann S., Hansen M.K., Leuenberger B., Luginbuehl U., et al. Phorbol 12-myristate 13-acetate-induced ectodomain shedding and phosphorylation of the human meprinbeta metalloprotease. J Biol Chem 2003, 278:42829-42839.
12. Haraoui B., Krelenbaum M. Emergence of Crohn's disease during treatment with the anti-tumor necrosis factor agent etanercept for ankylosing spondylitis: possible mechanisms of action. Semin Arthritis Rheum 2009, 39:176-181.
13. Hinkle C.L., Sunnarborg S.W., Loiselle D., Parker C.E., Stevenson M., Russell W.E., et al. Selective roles for tumor necrosis factor alpha-converting enzyme/ADAM17 in the shedding of the epidermal growth factor receptor ligand family: the juxtamembrane stalk determines cleavage efficiency. J Biol Chem 2004, 279:24179-24188.
14. Jap A., Chee S.P. Immunosuppressive therapy for ocular diseases. Curr Opin Ophthalmol 2008, 19:535-540.
15. Kalariya NM, Shoeb M, Reddy ABM, van Kuijk FJ, Ramana KV. Inhibition of TNF-α ectodomain shedding by TNF-α protease inhibitor suppresses ocular inflammation in rat EIU model. Unpublished observations.
16. Lyon F., Gale R.P., Lightman S. Recent developments in the treatment of uveitis: an update. Expert Opin Invest Drugs 2009, 18:609-616.
17. Maskos K., Fernandez-Catalan C., Huber R., Bourenkov G.P., Bartunik H., Ellestad G.A., et al. Crystal structure of the catalytic domain of human tumor necrosis factor-alpha-converting enzyme. Proc Natl Acad Sci USA 1998, 95:3408-3412.
18. Murumkar P.R., DasGupta S., Chandani S.R., Giridhar R., Yadav M.R. Novel TACE inhibitors in drug discovery: a review of patented compounds. Expert Opin Ther Pat 2010, 20:31-57.
19. Pérez L., Kerrigan J.E., Li X., Fan H. Substitution of methionine 435 with leucine, isoleucine, and serine in tumor necrosis factor alpha converting enzyme inactivates ectodomain shedding activity. Biochem Cell Biol 2007, 85:141-149.
20. Peschon J.J., Slack J.L., Reddy P., Stocking K.L., Sunnarborg S.W., Lee D.C., et al. An essential role for ectodomain shedding in mammalian development. Science 1998, 282:1281-1284.
21. Read R. Uveitis: advances in understanding of pathogenesis. Curr Rheumatol Rep 2006, 8:260-266.
22. Reddy A.B., Ramana K.V., Srivastava S., Bhatnagar A., Srivastava S.K. Aldose reductase regulates high glucose-induced ectodomain shedding of tumor necrosis factor (TNF)-alpha via protein kinase C-delta and TNF-alpha converting enzyme in vascular smooth muscle cells. Endocrinology 2009, 150:63-74.
23. Reeves S.W., Sloan F.A., Lee P.P., Jaffe G.J. Uveitis in the elderly: epidemiological data from the National Long-term Care Survey Medicare Cohort. Ophthalmology 2006, 113. 307.e1.
24. Sakimoto T., Yamada A., Kanno H., Sawa M. Upregulation of tumor necrosis factor receptor 1 and TNF-alpha converting enzyme during corneal wound healing. Jpn J Ophthalmol 2008, 52:393-398.
25. Sakimoto T., Yamada A., Sawa M. Release of soluble tumor necrosis factor receptor 1 from corneal epithelium by TNF-alpha-converting enzyme-dependent ectodomain shedding. Invest Ophthalmol Vis Sci 2009, 50:4618-4621.
26. Taylor P.C., Feldmann M. Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nat Rev Rheumatol 2009, 5:578-582.
27. Theodossiadis P.G., Markomichelakis N.N., Sfikakis P.P. Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation. Retina 2007, 27:399-413.
28. Wheeler D.L., Ness K.J., Oberley T.D., Verma A.K. Protein kinase Cepsilon is linked to 12-O-tetradecanoylphorbol-13-acetate-induced tumor necrosis factor-alpha ectodomain shedding and the development of metastatic squamous cell carcinoma in protein kinase Cepsilon transgenic mice. Cancer Res 2003, 63:6547-6555.